drugset
drugset / Trial / NCT03488251

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

NCT03488251 ↗

Phase 2 Terminated 8 enrolled Molecular Templates, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with gemcitabine and oxaliplatin (GEMOX) in participants with relapsed or refractory B-Cell NHL.

Timeline

Start
2018-08-20
Primary completion
2021-03-12
Completion
2021-03-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject MT-3724 Unknown 10 ug/kg Intravenous
Subject MT-3724 Unknown 25 ug/kg Intravenous
Subject MT-3724 Unknown 50 ug/kg Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Oxaliplatin Small molecule 100 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma